米吉珠单抗治疗中重度活动性溃疡性结肠炎的长期安全性:为期2年的整合安全性分析
本报告基于LUCENT-1、LUCENT-2和LUCENT-3三项3期研究,评估米吉珠单抗治疗中重度活动性溃疡性结肠炎患者长达104周的2年安全性。诱导应答者(N=333)与延长诱导应答者(N=149)的安全性总体一致,常见不良事件包括鼻咽炎、COVID-19、关节痛、UC加重和头痛,严重不良事件发生率低于10%,未发现新的重大安全性问题。
要点
- 诱导应答者(N=333)与延长诱导应答者(N=149)均接受米吉珠单抗持续治疗最长104周,安全性总体一致。
- 最常见不良事件为鼻咽炎、COVID-19、关节痛、UC症状加重和头痛,严重不良事件发生率低于10%。
- 注射部位反应随时间下降(诱导应答者10.2%,延长诱导应答者8.1%),亚组与总体安全性相似,仅高血压在60岁及以上患者中更常见。
核心结论
- 米吉珠单抗治疗中重度活动性UC的2年整合安全性在各亚组间一致,且与既往研究结果一致,未发现新的重大安全性问题。
研究设计与样本
- 基于3期研究LUCENT-1(NCT03518086)、LUCENT-2(NCT03524092)和LUCENT-3(NCT03519945)的整合安全性分析。
- 纳入完成诱导(LUCENT-1)和维持(LUCENT-2)并进入长期维持(LUCENT-3)的患者,分为诱导应答者(N=333)和延长诱导应答者(N=149)两个队列。
- 两个队列均接受米吉珠单抗持续治疗最长104周,并在60岁及以上患者及基线使用皮质类固醇、免疫调节剂或两者兼有的患者亚组中评估不良事件。
主要发现
- 诱导应答者和延长诱导应答者中最常见不良事件为鼻咽炎、COVID-19、关节痛、UC(症状加重/复发)和头痛。
- 两个队列中严重不良事件报告率均低于10%。
- 感染(多为轻度)发生率在诱导应答者为47.4%、延长诱导应答者为49.7%;脑血管心血管事件发生率分别为0.9%和1.3%;恶性肿瘤发生率分别为0%和3.4%。
- 注射部位反应发生率在诱导应答者为10.2%、延长诱导应答者为8.1%,且随时间下降。
- 患者亚组与总体人群的安全性特征相似,但高血压在60岁及以上患者中更常见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Ulcerative colitis (UC) is a chronic immune-mediated disease requiring ongoing treatment to maintain remission. This report presents the 2-year safety outcomes of mirikizumab, a humanized immunoglobulin G4 anti-interleukin-23p19 monoclonal antibody, in moderately to severely active UC from phase 3 studies LUCENT-1 (NCT03518086), LUCENT-2 (NCT03524092), and LUCENT-3 (NCT03519945). METHODS: Patients who underwent induction (LUCENT-1) and maintenance (LUCENT-2), and entered long-term maintenance (LUCENT-3) were assessed in 2 cohorts: induction responders and extended-induction responders. Both cohorts underwent up to 104 weeks of continuous treatment with mirikizumab. Adverse events (AEs) were assessed in these 2 cohorts and within subsets of patients aged 60 years or older and patients using corticosteroids, immunomodulators, or both at baseline. RESULTS: Safety was generally consistent across induction responders (N = 333) and extended-induction responders (N = 149) and across patient subsets. Nasopharyngitis, COVID-19, arthralgia, UC (worsening/reoccurrence of symptoms), and headache were the most common AEs. Serious AEs were reported in less than 10% of both cohorts. Infections (mostly mild), cerebrocardiovascular events, and malignancies occurred in 47.4% and 49.7%, 0.9% and 1.3%, and 0% and 3.4% of induction responders and extended-induction responders, respectively. Injection-site reactions (induction responders: 10.2% and extended-induction responders: 8.1%) declined over time. Safety profiles in patient subsets and in the whole population were similar, except for hypertension, which was more frequent in patients aged 60 years or older. DISCUSSION: The mirikizumab 2-year integrated safety profile in patients with moderately to severely active UC was consistent across subgroups and with previous findings, without new significant safety concerns.
引用
- Lee SD, Ehrlich AC, Pellanda P, et al. Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis. Am J Gastroenterol. 2025. PMID: 40071779. doi:10.14309/ajg.0000000000003407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。